nach oben

CNS Drugs

Erschienen in:

01.03.2011 | Adis Drug Profile

Cladribine Tablets

In Relapsing-Remitting Multiple Sclerosis

verfasst von: Victoria J. Muir, Greg L. Plosker

Erschienen in: CNS Drugs | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Cladribine, an immunosuppressant that selectively reduces peripheral lymphocyte levels, has potential as an oral therapy for relapsing-remitting multiple sclerosis. An oral (tablet) formulation is being investigated in clinical trials.

In the large, well designed, phase III CLARITY trial, short-course treatment with oral cladribine (cumulative dose of 3.5 or 5.25mg/kg) resulted in a significantly greater reduction in annualized relapse rates at 96 weeks compared with placebo in patients with relapsing-remitting multiple sclerosis.

Improvements in the annualized relapse rate with oral cladribine were independent of key baseline patient characteristics which included age, sex, previous treatment with disease-modifying drugs and the number of relapses in the previous 12 months.

In addition, a significantly higher proportion of patients were relapse-free at 96 weeks and there were significant reductions in the risk of 3-month sustained progression of disability in cladribine recipients compared with placebo recipients.

The mean numbers of brain lesions on magnetic resonance imaging were also significantly reduced with cladribine compared with placebo in the CLARITY trial.

Lymphocytopenia, herpes zoster infections and neoplasms (including malignancies) were more common in cladribine than placebo recipients.

Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006 Mar 4; 332(7540): 525–7CrossRef

The European Multiple Sclerosis Platform. Multiple sclerosis-fact sheet [online]. Available from URL:http://www.ms-in-europe.org/multiple-sclerosis/index.php?kategorie=whatisms&cnr=6&anr=127 [Accessed 2011 Jan 28]

Compston A, Coles A. Multiple sclerosis. Lancet 2008 Oct 25; 372(9648): 1502–17CrossRef

Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009 Jun; 8(6): 545–59CrossRef

Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 2007; 21(6): 483–502CrossRef

Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008; 68(17): 2445–68CrossRef

Kopadze T, Dobert M, Leussink VI, et al. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol 2009 Mar; 16(3): 409–12CrossRef

Bennett JL, Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 2009; 32(3): 121–32CrossRef

Langtry HD, Lamb HM. Cladribine: a review of its use in multiple sclerosis. Biodrugs 1998 May; 9(5): 419–33CrossRef

10.

Janssen-Cilag Ltd. Leustat injection: summary of product characteristics [online]. Available from URL:http://www.medicines.org.uk/emc/medicine/6737/SPC/Leustat++Injection./ [Accessed 2011 Jan 28]

11.

European Medicines Agency. Scientific discussion for the approval of Litak [online]. Available from URL:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000504/WC500041660.pdf [Accessed 2011 Jan 28]

12.

Bryson HM, Sorkin EM. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993 Nov; 46(5): 872–94PubMed

13.

Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362(5): 416–26CrossRef

14.

Australian Therapeutic Goods Administration. Australian public assessment report for cladribine tablets [online]. Available from URL:http://www.tga.gov.au/pmeds/auspar/auspar-movectro.pdf [Accessed 2011 Jan 28]

15.

Merck KGaA. Merck KGaA announces outcome of its request for reexamination of CHMP opinion for cladribine tablets in MS [online]. Available from URL:http://news.merck.de/N/0/9FA165BECF4916A8C125781E0065C3B1/$File/Clad2011-e.pdf [Accessed 2011 Jan 28]

16.

Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983 Oct; 62(4): 737–43CrossRef

17.

Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A 1980 Nov; 77(11): 6865–9CrossRef

18.

Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993 Feb 1; 81(3): 597–601CrossRef

19.

Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoro-adenine. Blood 1993 Jan 1; 81(1): 143–50CrossRef

20.

Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989 Dec 15; 49 (24 Pt 1): 6923–8PubMed

21.

Soelberg-Sørensen PS, Comi G, Cook S, et al. Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study [abstract no. P472 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 9–12; Düsseldorf

22.

Rieckmann P, Comi G, Cook S, et al. Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled clarity study [abstract no. P816 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 9–12; Düsseldorf

23.

Soelberg-Sørensen PS, Rieckmann P, Comi G, et al. Effects of cladribine tablets on circulating lymphocyte subset reconstitution in the 96-week CLARITY study in relapsingremitting multiple sclerosis (RRMS) [abstract no. P04.219 plus poster]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

24.

Salvat C, Curchod M, Guedj E, et al. Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis [abstract no. P280 plus poster]. 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2009 Sep 9–12; Düsseldorf

25.

Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, et al. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand 2004 Jun; 109(6): 390–2CrossRef

26.

Janiec K, Wajgt A, Kondera-Anasz Z. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Med Sci Monit 2001; 7(1): 93–8PubMed

27.

Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, et al. Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurol Scand 2010; 122(6): 409–13CrossRef

28.

Laugel B, Challier J, Siegfried C, et al. Cladribine exerts a modulatory effect on T-cell activation [abstract no. P80]. Mult Scler 2008; 14: S52–3

29.

Van Axel Castelli V, Trivieri G, Zucchelli I, et al. Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-beta-cyclodextrin. J Pharm Sci 2008 Sep; 97(9): 3897–906CrossRef

30.

Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997 Feb; 32(2): 120–31CrossRef

31.

Comi G, Cook S, Giovannoni G, et al. Reductions in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study [abstract no. P469 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 2–9; Düsseldorf

32.

Vermersch P, Comi G, Cook S, et al. Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study [abstract no. P817 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 2–9; Düsseldorf

33.

Giovannoni G, Comi G, Cook S, et al. Disease-free status achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis [abstract no. P471 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 2–9; Düsseldorf

34.

Rammohan K, Comi G, Cook S, et al. Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study [abstract no. P02.186 plus poster]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

35.

Giovannoni G, Comi G, Cook S, et al. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis [abstract no. P470 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 2–9; Düsseldorf

36.

Rammohan K, Comi G, Cook S, et al. Consistent efficacy of short-course cladribine tablets therapy across differing prognostic indicators for relapsing-remitting multiple sclerosis: Results from the phase III, double-blind, placebo-controlled, 96-week CLARITY study [abstract no. P441 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010 Oct 13–16; Göteborg

37.

Comi G, Giovannoni G, Rammohan K, et al. Consistent MRI benefits with short-course cladribine tablets therapy across the range of patients with relapsing-remitting multiple sclerosis in the double-blind, placebo-controlled, 96-week CLARITY study [abstract no. P403 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010 Oct 13–16; Göteburg

38.

Comi G, Cook S, Giovannoni G, et al. Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study [abstract no. P2375]. 14th Congresss of the European Federation of Neurological Societies; 2010 Sep 25–28; Geneva

39.

Giovannoni G, Comi G, Rammohan K, et al. Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study [abstract plus poster]. 14th Congress of the European Federation of Neurological Societies; 2010 Sep 25–28; Geneva

40.

Savic R, Munafo A, Karlsson M. The effect of cladribine tablets on disease progression in multiple sclerosis: a nonlinear mixed effect analysis [abstract no. P447 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010 Oct 13–16; Göteborg

41.

Havrdova E, Galetta S, Stefoski D, et al. Freedom from disease activity in multiple sclerosis. Neurology 2010 Apr 27; 74 Suppl. 3: S3–7CrossRef

42.

Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. Epub 2011 Jan 12

43.

Cook S, Vermersch P, Comi G, et al. Safety profile of cladribine tablets in the treatment of relapsing-remitting multiple sclerosis over 0–48 weeks compared with 48–96 weeks in the phase III, double-blind, placebo-controlled CLARITY study [abstract no. P817 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Göteborg

44.

European Medicines Agency. Refusal of the marketing authorisation for Movectro (cladribine) [online]. Available from URL:http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001197/WC500101072.pdf [Accessed 2011 Jan 28]

Titel: Cladribine Tablets
In Relapsing-Remitting Multiple Sclerosis
verfasst von: Victoria J. Muir
Greg L. Plosker
Publikationsdatum: 01.03.2011
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 3/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11204740-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Cladribine Tablets

In Relapsing-Remitting Multiple Sclerosis

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Sleep Disorders in Patients with Traumatic Brain Injury

Managing Cognitive Dysfunction through the Continuum of Alzheimer’s Disease

Excessive Daytime Sleepiness in Patients with Parkinson’s Disease

Pain Freedom at 2 Hours in Migraine after Telcagepant 300 mg

Asenapine

Role of Cannabinoids in Multiple Sclerosis

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie